Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
Methods for modulating factor 12 expression
US9150864B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9150864-B2 |
| Application number | US-201113884067-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 8, 2011 |
| Priority date | Nov 8, 2010 |
| Publication date | Oct 6, 2015 |
| Grant date | Oct 6, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and mesenteric thrombosis. Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an animal having a thromboembolic condition or at risk for developing a thromboembolic condition comprising administering to the animal a therapeutically effective amount of a compound comprising an oligonucleotide consisting of 12-25 linked nucleosides targeted to a Factor 12 nucleic acid, wherein the oligonucleotide has a nucleobase sequence that is at least 90% complementary to SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 as measured o…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C12N15/113Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C12N15/1137Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9150864B2 cover?
- Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke,…
- Who is the assignee on this patent?
- Monia Brett P, Macleod Robert A, Crosby Jeffrey R, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).